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Reproducibility via coordinated 
standardization: a multi-center 
study in a Shank2 genetic rat model 
for Autism Spectrum Disorders
María Arroyo-Araujo1, Radka Graf2, Martine Maco3, elsbeth van Dam4, esther Schenker5, 
Wilhelmus Drinkenburg6, Bastijn Koopmans7, Sietse f. de Boer1, Michaela cullum-
Doyle2, Lucas p. J. J. noldus4, Maarten Loos  7, Wil van Dommelen4, Will Spooren2, 
Barbara Biemans3, Derek L. Buhl2 & Martien J. Kas  1,8
Inconsistent findings between laboratories are hampering scientific progress and are of increasing 
public concern. Differences in laboratory environment is a known factor contributing to poor 
reproducibility of findings between research sites, and well-controlled multisite efforts are an 
important next step to identify the relevant factors needed to reduce variation in study outcome 
between laboratories. Through harmonization of apparatus, test protocol, and aligned and non-aligned 
environmental variables, the present study shows that behavioral pharmacological responses in Shank2 
knockout (KO) rats, a model of synaptic dysfunction relevant to autism spectrum disorders, were highly 
replicable across three research centers. All three sites reliably observed a hyperactive and repetitive 
behavioral phenotype in KO rats compared to their wild-type littermates as well as a dose-dependent 
phenotype attenuation following acute injections of a selective mGluR1 antagonist. These results show 
that reproducibility in preclinical studies can be obtained and emphasizes the need for high quality and 
rigorous methodologies in scientific research. Considering the observed external validity, the present 
study also suggests mGluR1 as potential target for the treatment of autism spectrum disorders.
The alarmingly high estimate of failure (50–80%) to replicate findings in preclinical studies is a prevalent issue 
of great scientific and public concern that needs to be addressed1–3. While the lack of reproducibility of scientific 
findings has gained significant attention, thus far not many attempts and strategies have been implemented to 
tackle this challenging situation. Given that the ability to replicate empirical findings is a prerequisite of exper-
imental science, deficient reproducibility hinders scientific credibility and progress. For biomedical animal 
research in particular, poor reproducibility questions the benefit of research in the ethical analysis of animal 
experiments4, prevents pharmacotherapeutic development, and results in great monetary loss5,6. The inability 
to replicate scientific findings points toward systematic inefficiencies in the way studies are planned, executed, 
analyzed, and reported.
Although drivers of data variability across different research sites are not well understood, the use of different 
animal strains, housing, husbandry, and testing environments, and/or different lab standard operating proce-
dures (SOPs) are generally considered critical factors7,8. Therefore, rigorous genetic (animals) and environmental 
(housing, husbandry, testing procedures) standardization have been advocated as good laboratory practice to 
reduce variation in experimental results9. However, excessive standardization results in more homogeneous study 
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populations, which in turn generates spurious results as they are representative to the specific standardized con-
ditions under which the data was obtained, thereby hampering replicability8,10–12.
Gene-environment interactions can considerably affect animal behavior. As laboratories differ in many factors 
(personnel, odors, noise, microbiota, etc.) and the intrinsic variability of the animals assessed is high (i.e. genetic 
variation from different vendors), the variation of phenotypes between laboratories, even in the same genetic 
strain of animals, is generally much larger than the variation within laboratories as clearly shown by the landmark 
multi-laboratory study of Crabbe et al.13. Then, contrary to common belief, excessive standardization, understood 
as controlled environmental enrichment that decreases biologically meaningful variation, doesn’t contribute to 
highly reproducible results.
To improve reproducibility of preclinical studies and maximize the chances of discovering meaningful treat-
ment effects or fundamental biological principles, several suggestions have been proposed6,14,15; in particular, to 
take into account unavoidable between-laboratory variations. For this, the use of multi-laboratory study designs 
has been advocated as a valuable approach to evaluate the influence of heterogenization between different labo-
ratory settings on data variability8. Using the genetically modified Shank2 knockout (KO) rat model of synaptic 
dysfunction relevant to autism spectrum disorders reported to exhibit autistic-like hyperactive and repetitive 
behavioral phenotype16, the primary objective of the current study was to investigate whether these previously 
reported results could be reproduced and replicated across three study sites by following the same experimen-
tal protocol for behavioral evaluation with automated video scoring analysis and drug testing. To reduce the 
impact of environmental factors that typically differ greatly between laboratories and are difficult to control, an 
identical test setup, i.e. a PhenoTyper® cage and EthoVision XT 12 video tracking software (Noldus Information 
Technology BV; Wageningen, The Netherlands) was used at all sites. Shank2 KO rats were placed in this novel 
environment in an attempt to reproduce the previously observed hyperactive and repetitive behavioral phenotype 
of these animals16 that recapitulate the characteristic behavioral abnormalities of autism spectrum disorder (ASD) 
in humans. In addition, to confirm the normalization after pharmacological treatment with the metabotropic 
Glutamate Receptor 1 (mGluR1) antagonist JNJ16259685, we included a dose-response of the drug treatment 
to strengthen interpretation for the effect. Finally, as a secondary objective, a comparison between 2 behavioral 
scoring methods to evaluate the phenotype (i.e., automated versus manual scoring) was performed using the 
same recorded videos.
Materials and Methods
General study design. Based on the demonstration of hyperactivity and repetitive circling behaviors 
observed in the Shank2 KO rat model16, a cross-site study focusing on these behaviors was initiated. Specifically, 
we aimed to assess the behavioral phenotype, as well as the pharmacological effects in both Shank2 KO and 
littermate controls (WT) using automated video scoring. A phenotypic assessment was carried out quasi-simul-
taneously (i.e. during the same month) in three different research facilities. Although the aim of this study was to 
explore the reproducibility of the results, it was not intended to fully reproduce the original methodology; stand-
ardized phenotyping equipment was used, and small changes were made to the protocol for this study.
To optimize the chance of successful replication, the protocol entailed controlling several aspects of the study 
design from animal provider and shipment, to details of experimental procedures. In addition, some other factors 
were not harmonized across sites presumably revealing the robustness of the study results.
To enable consistency in the environmental aspects of the behavioral assays and automated scoring methods 
between sites, and in addition to the PhenoTyper chambers provided, the operational definition of the behavioral 
categories to score were aligned across sites to pursue consistency in the manual scoring (e.g. what represents a 
turn). Janssen Pharmaceutica NV (Beerse, Belgium) provided the mGluR1 antagonist JNJ1625968515,17 to all sites 
to eliminate variability in pharmacological outcomes due to inconsistencies of the chemical batch (e.g. differences 
in purity).
Laboratories. The experiment was conducted at the Groningen Institute for Evolutionary Life Sciences 
(GELIFES) of the University of Groningen (RUG, Groningen, The Netherlands), the Neuroscience and 
Pain Research Unit of Pfizer Inc. (Cambridge, MA, USA), and at the Roche Innovation Center Basel (Basel, 
Switzerland).
Study design. The experiment was carried out during four consecutive weeks of four testing days per week 
(Monday to Thursday), always starting 4 hours after onset of light.
A full crossover design was followed, so that each subject received each dose once with a one-week wash-out 
period before the next dosing and testing; for this, on each day of the week 3 WT and 3 KO were tested, so that 
at the end of the week all subjects (12WT/12KO) were tested once with one of the four treatments (including 
vehicle).
On a given testing day, each subject was weighed and given a single-dose injection of either vehicle (saline) 
or JNJ16259685 (0.02, 0.04, or 0.63 mg/kg in 5 ml/kg volume), administered subcutaneously in the flank. The 
dosing order was alternated between genotypes and counterbalanced across days. The treatment conditions were 
randomized throughout the experiment with a Latin-square design.
Thirty minutes after dosing, the subject was placed in a PhenoTyper chamber and video-recorded for 30 min-
utes after which the chamber was cleaned with alcohol wipes. The behavior was scored after the experiment from 
the video images using EthoVision XT 12 for the automated scoring or The Observer XT 13 for the manual scor-
ing. For the latter, the observer was blinded to genotype and treatment.
Animals. 36 Sprague-Dawley male rats carrying a targeted deletion of the Shank2 gene (KO) and 36 male 
WT rats matched for age were generated as described by Modi et al., 2018. A batch of 12 KO and 12 WT rats was 
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shipped from Charles River Laboratories (Wilmington, MA, USA) to each of the three sites involved. Animals 
had at least ~4 weeks of habituation to their housing facility and were around 3 months old at the start of the 
experiment.
Animals had ad libitum access to food and water with a similar 12:12 light-dark cycle at all three sites.
All animal procedures were carried out following the regulations of the Directive 2010/63/EU and in accord-
ance with the recommendations of the Guide for the Care and Use of Laboratory Animals. The protocol was 
approved by the Pfizer Institutional Animal Care and Use Committee, the Basel Cantonal Animal Protection 
Committee adhering to Swiss federal legislation, and the University of Groningen’s Animal Welfare Body in 
accordance with the Central Committee for Animal Experiments.
Drug. The test compound, JNJ16259685-AAA (3,4-dihydro-2H-pyrano[2,3]b-quinolin-7-yl) 
(cis-4-methoxycyclohexyl) methanone, is a brain penetrant selective mGluR1 antagonist with an affinity of 
0.34 nM (Ki value) for rat mGlu1 receptor, which potently and completely inhibits glutamate-induced increases in 
intracellular Ca2+ concentrations with an IC50 value of 3.24 nM (Lavreysen et al. 2004). The compound was syn-
thesized at Janssen Pharmaceutica NV and centrally shipped to the participating labs, by the Compound Logistics 
& Formulation unit at Janssen Pharmaceutica NV. All sites used compound from the same chemical batch.
JNJ16259685-AAA was dissolved in saline (i.e. H2O + HCL + NaCL to reach a pH of 7.4) and serial dilutions 
were made for the different doses.
Equipment and software. A PhenoTyper 4500 behavioral assessment chamber (Noldus Information 
Technology BV) was shipped to each of the three sites, to ascertain standardization of behavioral recording and 
analysis. The PhenoTyper 4500 chamber includes a black square arena (floor area 45 × 45 cm), 4 matted walls with 
ventilation holes at the top (66 cm tall). The top unit serves as a lid from which only the infrared sensitive camera 
(30 fps at 640 × 480 resolution using NTSC format) and the 3 arrays of dimmable infrared LED lights were used.
Automated scoring of rat’s behavior was done using EthoVision XT 12 video tracking software, including the 
Rat Behavior Recognition module (Noldus Information Technologies BV) which allowed a repeatable, objective, 
and consistent analysis of the 30 minutes video. Details of the acquisition settings are listed in Table 1 of the 
Supplementary material.
The video files that were run offline through EthoVision XT 12, were scored using The Observer XT 13 soft-
ware by a blinded scorer at each of the three sites; for this, only the second 10-minute bin was analyzed.
Behavioral readouts (automated and manual). Following a predetermined set of criteria (Tables 1 and 2), 
behavior was analyzed using two methods of scoring. The predetermined criteria were discussed and agreed upon 
in detail by the three sites.
Automated scoring. Table 1 lists the behaviors and their definition as recognized by EthoVision XT 12. The auto-
mated scores of these behaviors are based on the entire 30 minutes of the experimental session.
Manual scoring. The manual scoring of behaviors was done by a trained observer blind to genotype and treat-
ment, using The Observer XT 13. Table 2 depicts the behavioral definitions on which the scoring was based. This 
scoring was only carried out for the second 10-minute bin of the experimental session (i.e. from minute 11 to 
minute 20).
Data management. The data were archived on the cloud platform of Sylics (Synaptologics; Amsterdam, 
The Netherlands) which allowed us to share video files, raw data, and spreadsheets between the three sites in an 
efficient and secure way.
Statistics. The behavioral outcomes were analyzed using SPSS according to the different objectives defined:
Variable Description
Circling Rotation based on direction from tail-base to center-point, clockwise, count every 0.75 rotation, threshold 30 degrees (frequency)
Circling 2 Rotation based on direction from tail-base to center-point, counterclockwise, count every 0.75 rotation, threshold 30 degrees (frequency)
Rearing Supported Probability greater than 50%, excludes instances shorter than 0.50 s (frequency, cumulative duration)
Rearing Unsupported Probability greater than 80%, excludes instances shorter than 0.50 s (frequency, cumulative duration)
Movement Averaging interval of 1 sample, start velocity 5.00 cm/s, stop velocity 1.00 cm/s based on the body center-point (mean, cumulative duration)
Walking Probability greater than 10%, exclude instances shorter than 0.00 s (frequency, cumulative duration)
Table 1. Description of the detection criteria for the automated tracking using EthoVision XT 12.
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Reproducibility across sites. A three-way ANOVA with genotype (two levels) and site (three levels) as 
between-subject factors, and treatment as the repeated within-subject factor [four levels (vehicle, 3 doses)] was 
performed on absolute data values for each of the readouts. In the case of a main site and genotype effect in 
this absolute data set, normalized values (relative to vehicle treatment) were analyzed using the same three-way 
ANOVA design. This analysis aimed to address reproducibility across sites in terms of the phenotype evaluation 
as well as the pharmacological intervention.
Method of scoring. To explore the effect of different methods of scoring, manual scored data was compared 
to automated data using the same three behavioral outcomes (walking, rearing and circling). Only the middle 
10-minute bin of the entire 30-minute observation period was analyzed by employing a 4-way ANOVA with 
genotype and site as between-subject factors, and method of scoring [two levels: manual (The Observer XT 13) 
and automatic (EthoVision XT 12)] and treatment as repeated within-subject factors.
Results
Standardization across sites. To ensure high-quality data, the protocol shared across sites addressed ran-
domization and blinding principles in addition to detailed environmental variables, handling and testing proce-
dures summarized in Table 3. The experimental protocol for this study was based on a previous single-site study 
using the same compound and different automated scoring equipment16,17. The study design was then discussed 
between the consortium partners to address alignment of factors with anticipated higher relevance to maximize 
the power of the study. A summary of aligned and non-aligned factors is presented in Table 3.
Behavioral evaluation. The behavioral read-outs were (1) circling behavior, expressed as the frequency of 
circling (clockwise and counterclockwise), (2) rearing, expressed as frequency of supported and unsupported 
rearing, and (3) time spent walking. These behavioral read-outs were analyzed in separate ANOVA’s.
Hyperactive and repetitive phenotypes of Shank2 KOs were consistently observed across study sites. Analysis of 
the automated scorings (EthoVision XT 12), during the 30-minute PhenoTyper chamber exposure, revealed that 
Shank2 KO rats showed increased walking (Fig. 1A; genotype F(1,65) = 94.95, p < 0.001), rearing (Fig. 1B; gen-
otype F(1,65) = 35.9, p < 0.001), and circling behavior (Fig. 1C; genotype F(1,65) = 22.69, p < 0.001) relative to 
the WTs across all three study sites. However, a significant genotype x site interaction, and genotype x treatment 
interaction effect was observed for walking (F(2,65) = 5.9, p < 0.005; (F(3,195) = 29.9, p < 0.001) and circling 
(F(2,65) = 3.0, p < 0.05; F(3,195) = 5.6, p < 0.001) while for rearing only the latter interaction reached significance 
(F(3,195) = 13.5,p < 0.001). In addition, a significant overall site effect for rearing (F(2,65) = 7.1, p < 0.005) and 
circling (F(2,65) = 3.6, p < 0.05) was found. Univariate ANOVA of only the vehicle data showed a significant 
genotype effect for walking, rearing and circling across all three sites (Fig. 1A–C). To display the hyperactive 
and repetitive behavioral phenotype of Shank2 KO rats, the vehicle data from all three sites were pooled for both 
phenotypes (Fig. 1J–L) and analyzed with ANOVA (walking: F(1,70) = 48.9, p < 0.001; rearing: F(1,69) = 31.8, 
p < 0.001; circling: F(1,70) = 55.6, p < 0.001).
Further analyses suggested that the site x genotype interaction effect for walking was explained by the higher 
Pfizer scores of the WT group compared to the RUG and Roche values (F(2,32) = 13.98, p < 0.001). The site effect 
for rearing was due to the lower Roche scoring values of both groups of animals compared to the RUG and Pfizer 
data sets (F(2,65) = 7.12, p < 0.005). The site and site x genotype interaction effect for circling was mainly caused 
by the general lower Pfizer values of, primarily, the Shank2 KO group (F(2,33) = 5.19, p < 0.02) and mildly by the 
WT (F(2,32) = 22.58, p < 0.001) compared to the RUG and Roche values. Yet, all these study-site and genotype 
main- and interaction-effects disappeared when normalizing the raw data by expressing them as relative to the 
vehicle control (Fig. 1D–F, Supplementary Table 2).
Consistent dose-dependent attenuation of motor activity and circling behavior in Shank2 KO and WT rats by 
JNJ16259685 treatment across study sites. JNJ16259685 treatment resulted in a robust dose-dependent 
suppression of walking, rearing, and circling behavior in both WT and Shank2 KO rats at all three study 
sites. For all three behavioral parameters, a significant overall main effect of treatment was found (walking 
(Fig. 1A): F(3,195) = 125.3, p < 0.001), rearing (Fig. 1B): F(3,195) = 192.6, p < 0.001), and circling (Fig. 1C): 
Behavior How to manually score rat behavior in The Observer XT
Circling (total time)
Start scoring when the rat moves in rapid circles in the same direction lacking 
apparent goal or function, do not stop until the rat finishes circling. Don’t score 
each full rotation separately, score it as a bout
Circling (frequency) Score each event when the rat turns in a full circular motion (as reference, the nose has to travel at least 270 degrees)
Rearing Unsupported/Supported
Start to score this behavior when the rat puts its weight on its hind legs, raises its 
forepaws from the ground, and extents its head upward. Its forepaws can either 
lean on the wall or stay suspended
Inactive
The rat is  sitting still on the floor, without performing any of the other scored 
behaviors, and showing from little to no movement based on the rat’s body 
center-point
Walking Start behavior when the rat’s body center-point begins to move
Table 2. Description of the behavioral definitions used for the manual scoring with The Observer XT 13.
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F(3,195) = 12.19, p < 0.001) as well as a significant treatment x genotype interaction (Supplementary Table 2). 
This interaction effect is predominantly caused by the robustly enhanced hyperactivity and repetitive circling 
behavior of the KO animals and completely disappears when normalizing the raw data by expressing them as rel-
ative to the vehicle condition (Fig. 1D–F, Supplementary Table 2). This indicates that the JNJ16259685 treatment 
effects were similar for KO and WT rats and, importantly, consistent across all three sites. Combining the data 
from all three sites (Fig. 1G–I) demonstrated similar dose-response curves for JNJ16259685 treatment to inhibit 
walking (ID50 = 0.9549 and 0.583 for WTs and KOs, respectively), rearing (ID50 = 0.6755 and 0.6883 for WTs and 
Factor RUG Pfizer Roche Aligned?
Provider of animals Charles River Charles River Charles River Y
Age at start of experiment ~3 months ~3 months ~3 months Y
Average bodyweight at 
the start of experiment WT 407gr (±33)/KO 399gr (±45) 300–350gr WT 428 gr (±32)/KO 377gr (±33) N
Animal-related guidelines
Housing Single housed Single housed Single housed Y
Cage size Makrolon type 2 L Innovive Rat Cage Makrolon type IV N
Bedding Lignocel BK8/15 Alpha Dri Lignocel FS-14 N
Food type Standard Altronim rodent chow Standard Purina rat chow (5053) KLIBA NAFAG 3436 N
Cage cleaning 1/week Friday 1/week Friday 1/week Friday Y
Enrichment Wooden bar, nesting material (Enviro-dry) Plastic bone, nesting material (Bed-R’Nest) Wooden bar, nesting material Y#
Handling Tail tail Body N
Experimenter Master student (MAA) Undergraduate Researcher (MCD) Laboratory Associate (MM) N
Gloves Yes Yes Yes Y
Disturbance other rats housed Not applicable Radio (60 dB) N
Identification Cage card, ear-clip and tail mark Cage card and tail mark Cage card N
Physical environment of the housing room (HR)
Humidity 42% 45% 50% N
Temperature 73πF 72πF 70πF N
Lighting ~35 Lux ~35 Lux ~150 Lux N
Behavioral testing
Testing days Mon-Thur. Mon-Thur. Mon-Thur. Y
Test room Separate Same as Holding room (HR) Same as HR N
Lighting in procedure 
room ~35 lux ~35 Lux ~150 Lux N
Volume 35–40 dB 60 dB 60 dB N
Temperature 73 °F 72 °F 70 °F N
Humidity 42% 45% 50% N
Randomization Latin-square Latin-square Latin-square Y
Sample size per genotype 11 WT/12 KO 12 WT/12 KO 12 WT/12 KO Y*
Dosing s.c. in the flank s.c. in the flank s.c. in the flank Y
in holding room in procedure room in procedure room N
Post-dosing time 30 min 30 min 30 min Y
Environment and Equipment
PC outside procedure room in procedure room in procedure room N
Experimenter present No yes, behind blinders Yes N
Equipment PhenoTyper 4500 PhenoTyper 4500 PhenoTyper 4500 Y
Light inside PhenoTyper ~14.5 Lux ~14 Lux ~80 Lux N**
Cleaning alcohol wipes alcohol wipes alcohol wipes Y
Software
Automated scoring EthoVision XT 12 EthoVision XT 12 EthoVision XT 12 Y
Manual scoring The Observer XT 13 The Observer XT 13 The Observer XT 13 Y
Blinded scoring yes yes Yes Y
Compound
Provider Janssen Pharmaceutica NV Janssen Pharmaceutica NV Janssen Pharmaceutica NV Y
Table 3. Summary of the experimental factors that were aligned across sites. *One rat missed the last dosing so 
it was excluded from the analyses. #Home cage enrichment was agreed to be applied at all three sites but adhered 
to institutional standard practices. **Light intensity inside the chamber was aligned but technical aspects 
prevented one of the sites to use the agreed intensity.
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KOs respectively), and circling behavior (ID50 = 1.034 and 0.535 for WTs and KOs respectively) for both WT and 
Shank2 KO animals.
Treatment effects are comparable whether scored automatically or manually. The present study was focusing on 
the reproducibility of automated scored behavior from a previous study16. To test whether the level of reproduc-
ibility of the automated scoring was comparable to that of manual scoring, a method frequently used in behav-
ioral pharmacology studies, we compared manual and automated scored behaviors in a 10-minute segment of 
the data across sites. Manual (The Observer XT 13) and automated (EthoVision XT 12) scorings of the second 
10-minute bin of the recordings were employed and included in the ANOVA as an additional (within-subject) 
factor; this 10-minute time segment was selected because it had the highest rate of activity in the 60-minute 
evaluation of Modi et al., 2018. A four-way ANOVA analysis revealed a significant main effect of method for 
Figure 1. (A–C)Absolute values for walking (A), rearing (B), and circling (C) across the three sites from 
automated scoring analysis (full 30’ session). (D–F) Normalized values relative to the vehicle for walking 
(D), rearing (E), and circling (F) across the three sites. The averaged site values for the respective dose levels 
(depicted in D–F) are shown in (G–I). Pooled data from the three sites under vehicle condition for both 
genotypes for walking (J), rearing (K), and circling (L) behavior. All values are expressed as mean ± S.E.M. 
*Statistically significant differences (p < 0.05), #Points out trend (p = 0.06).
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all three behavioral parameters (see Fig. 2A–C for walking; Fig. 2D–F for rearing, and Fig. 2G–I for circling, 
and Supplementary Table 3) as well as several method interaction effects with genotype, site, and treatment (see 
Supplementary Table 3).
Overall, the automated EthoVision-scored values for walking, rearing, and circling were higher than the 
manual Observer-scored values (F(1,65) = 112.1, p < 0.001; F(1,65) = 47.8, p < 0.001; and F(1,65) = 52.9, 
p < 0.001; respectively). The hyperactive and repetitive circling behavioral phenotype of the KOs as well as its 
dose-dependent suppression by JNJ16259685 treatment were reliably detected at all three study sites by man-
ual scoring (Walking: Fig. 2A–C; Rearing: Fig. 2D–F; Circling: Fig. 2G–I). Interestingly, while manual- and 
automated-scored circling displayed visibly different scores across sites, no significant main or interaction effects 
appeared following normalization of the raw data relative to the vehicle condition. However, for the normalized 
rearing data for the 10-minute bin (data not shown), a significant main effect of method and method x treatment 
interaction persisted (Supplementary Table 3). Further analyses revealed higher values at the JNJ16259685 0.04 
and 0.63 mg/kg treatments for the automated method relative to the manual scoring method.
Discussion
The present study demonstrates that rigorous alignment of experimental protocols between three research centers 
resulted in comparable experimental findings across sites for both genotype and treatment effects. The phenotypic 
difference between the Shank2 KO and WT rats was reliably observed in all three study sites. While there were 
differences in amplitude of the genotype effect on behavior, all three sites observed that the KO rats displayed 
consistently heightened motor activity (i.e. walking and rearing) and stereotypic circling behavior when com-
pared to WT rats. This finding indicates reproducible findings across sites, in addition to the replication of the 
original report16. Importantly, our data demonstrates the robustness of the Shank2 deletion-induced behavioral 
phenotypes that may mimic some of the behavioral abnormalities observed in ASD. Likewise, a consistent and 
dose-dependent attenuation of motor activity and circling behavior in both KO and WT rats by JNJ16259685 was 
found across the three study sites.
This high level of reproducibility is likely to be attributed to the rigorously standardized experimental proto-
col. The study design employed herein was adapted from the original work of Modi et al., 2018 with particular 
effort to prevent bias in the design, collection, and analysis of data (e.g. blinding, randomization, carry-over 
effects, etc.); and to analyze the data similarly through automated scoring. Besides the study design, experimen-
tal conditions that may have biological relevance to the expression of the phenotype (e.g., age of the animals) 
were aligned across sites. Conversely, factors that were not expected to have direct biological relevance related 
to phenotype expression were addressed; however, at a variable level between sites (e.g., environmental enrich-
ment applied for all sites, but the level of environmental enrichment for the housing conditions differed across 
sites). Thus, environmental variability between the three sites was allowed, which introduced heterogenization 
for experimental conditions that were site specific10,18. Therefore, our study appears to support the assumption 
that a combination of standardized and heterogenized factors can lead to a high level of reproducibility between 
different laboratories. Selection of these factors may be dependent on study aim and neurobiological construct 
that is being investigated; indeed, for future study designs, it is recommended to carefully review the standard-
ization of environmental factors and consider their relevance in light of the phenotype of interest. For example, 
by over-standardizing only factors that are not biologically relevant to the expression of the (behavioral) pheno-
type of interest, the result is at risk of being highly idiosyncratic. On the other hand, and as recently suggested, 
introducing systematic heterogenization of certain factors can boost external validity and thus reproducibility19.
Preclinical studies are a stepping stone in the pipeline for new pharmacotherapeutic treatments of human 
disorders. Thus, the development and assessment of animal models that recapitulate specific phenotypes of the 
disorders in a consistent manner is crucial when testing new therapeutic targets. In addition to protocol align-
ment for factors related to the laboratory (micro-)environment, selection of the type of animal model is also 
important in view of reproducibility (e.g., when the originally observed effect sizes in outcome measures for the 
selected model are small).
Here, the initial hyperactive and repetitive behavioral phenotypes of Shank2 KO rats were robust as these 
behavioral alterations are consistently observed across various different Shank-mutations in both rats and mice 
under a variety of experimental testing conditions20–25 suggesting the authentic relevance of these postsynaptic 
scaffolding proteins that are present at glutaminergic synapses for ASD-like behaviors and the suitability for 
pharmacological testing. Nonetheless, attention must be drawn to the different underlying circuitry responsible 
for the robust phenotype since it might not completely overlap across the different Shank mutations, as previously 
reported by Yoo et al. 2014 who found inconsistencies in molecular, physiological and behavioral data between 
and within the Shank mutant mouse lines26.
Recapitulating and expanding on the findings from Modi et al. (2018), administration of the selective and 
high-affinity mGluR1 antagonist JNJ16259685 effectively attenuated the hyperactivity and repetitive circling 
behavior of Shank2 KO rats in a dose-dependent manner. While Modi et al. demonstrated a significant attenu-
ation of these behavioral phenotypes in both WT and KO animals, they argued that JNJ16249685 (0.63 mg/kg) 
normalized KO behavior to WT vehicle-dosed levels. Here, we show that the locomotor-suppressing effects of 
JNJ16259685 produce similar dose-effect curves in both genotypes. This goes well in line with the fact that the 
mGluR1 receptors are richly distributed in regions associated with motor function including the cerebellum27,28 
and basal ganglia29, and are believed to play an important role in movement, motor coordination, and motiva-
tion30,31. Our findings agree with the results of Hodgson et al., 2011, who reported a dose-dependent reduction 
in novelty-induced locomotor and rearing activity of Wistar rats. Hence, they support the assertion that the 
mGluR1 is involved in general motivation to explore their environment31. Although this study was focusing 
on reproducing the behavioural features in the Shank2 KO rats, electrophysiological characterization can be 
reviewed in Modi, et al. (2018). Overall, our results support the suggestion that the hyperactive phenotype of 
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Shank2-deficient rats is associated with enhanced striatal mGluR1 signaling16 thereby providing face, construct 
and predictive validity of this animal model for ASD. This study also suggests mGluR1 as potential target for the 
treatment of ASD.
Another aim of this study was to compare two different methods of scoring behavior, automated versus man-
ual scoring. Behavioral studies are relevant for most biological, evolutionary, and biomedical research questions, 
creating a need for high-throughput experiments and mechanistic insight; however, the effort and time spent 
in manual scoring and data processing becomes a burden when conducting behavioral experiments. Therefore, 
there is a need for an automated screening of an animal’s behavior capable to discriminate between different 
behavioral categories, especially in the presence of animal manipulations. For the current study, three behavioral 
categories were chosen to compare between an automated and a manual scoring; these categories have a different 
level of complexity in terms of how straightforward it is to score the behavior. The selected categories are walking 
time, rearing frequency and circling frequency, from the most to least simple.
Overall, the automated scoring showed higher rates compared to the manual scoring at all three sites. The 
mismatch between methods was present for both genotypes and across treatments indicating that the differ-
ences between methods might originate from the flexibility of the behavioral definition adopted for each scor-
ing method; in addition, discrepancies might also be attributed to the human observer ‘smoothing’ the scoring, 
Figure 2. Absolute values across treatments for walking time (A–C), rearing frequency (D–F), and circling 
frequency (G–I) for the second 10-minute bin of the automated (triangles) and manual scored (circles) data, 
comparing the KO (black shapes) and WT (white shapes) rats. All data points express the mean ± S.E.M.
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meaning that brief intervals between behaviors are scored as the continuity of the behavior, while the automated 
scoring counts separate events. This suggests that special attention must be drawn not only to the definition of 
the behavior being scored, but also to the parameters that frame this definition, likely in this case smoothing by 
the human scorer and the continuity of the behavior scored as separate events by the automated scoring. These 
parameters have to be adapted according to the behavior being defined and the instrument used. Moreover, the 
concordance between methods was higher for the simplest behavioral category (walking time) and the lowest for 
the most complex category (circling frequency) suggesting that the coherence between scoring methods is more 
easily attainable when the behavioral category is unambiguous. Importantly, both the manual and automated 
scoring methods succeeded in detecting the phenotype and treatment effects (Supplementary Table 3), suggesting 
that they are both reliable methods to assess the relatively simple behaviors scored in the current study.
To conclude, by using a combination of standardization and heterogenization for experimental factors, a har-
monized protocol was generated and applied to a multicenter study in which genotype and treatment effects were 
studied at a behavioral level. Here we showed that, following careful alignment of these factors, reproducibility of 
genotype and treatment effects in rodents can be established for both automated- and manually-scored behaviors.
References
 1. Baker, J. D. The Purpose, Process, and Methods of Writing a Literature Review. AORN J. 103, 265–269 (2016).
 2. Goodman, S. N., Fanelli, D. & Ioannidis, J. P. A. What does research reproducibility mean? Sci. Transl. Med. 8, 341ps12–341ps12 
(2016).
 3. Loken, E. & Gelman, A. Measurement error and the replication crisis. Science 355, 584–585 (2017).
 4. Würbel, H. More than 3Rs: the importance of scientific validity for harm-benefit analysis of animal research. Lab Anim. 46, 164–166 
(2017).
 5. Freedman, L. P., Cockburn, I. M. & Simcoe, T. S. The Economics of Reproducibility in Preclinical Research. PLOS Biol. 13, e1002165 
(2015).
 6. Kafkafi, N. et al. Reproducibility and replicability of rodent phenotyping in preclinical studies. Neurosci. Biobehav. Rev. 87, 218–232 
(2018).
 7. Gerlai, R. Reproducibility and replicability in zebrafish behavioral neuroscience research. Pharmacol. Biochem. Behav (2018)
 8. Voelkl, B., Vogt, L., Sena, E. S. & Würbel, H. Reproducibility of preclinical animal research improves with heterogeneity of study 
samples. PLOS Biol. 16, e2003693 (2018).
 9. Beynen, A. C., Gartner, K. & van Zutphen, L. F. M. Standardization of animal experimentation. In: Zutphen LFM Baumans V Beynen 
AC editors. Principles of laboratory animal science. 2nd ed. Amsterdam: Elsevier Ltd 2003. pp. 103–110.
 10. Richter, S. H., Garner, J. P., Auer, C., Kunert, J. & Würbel, H. Systematic variation improves reproducibility of animal experiments. 
Nat. Methods 7, 167–168 (2010).
 11. Voelkl, B. & Würbel, H. Reproducibility Crisis: Are We Ignoring Reaction Norms? Trends Pharmacol. Sci. 37, 509–510 (2016).
 12. Würbel, H. Behaviour and the standardization fallacy. Nat. Genet. 26, 263 (2000).
 13. Crabbe, J. C., Wahlsten, D. & Dudek, B. C. Genetics of mouse behavior: interactions with laboratory environment. Science 284, 
1670–1672 (1999).
 14. Collins, F. S. & Tabak, L. A. Policy: NIH plans to enhance reproducibility. Nat. News 505, 612 (2014).
 15. Steckler, T. Editorial: preclinical data reproducibility for R&D - the challenge for neuroscience. SpringerPlus 4, 1 (2015).
 16. Modi, M. E. et al. Hyperactivity and Hypermotivation Associated With Increased Striatal mGluR1 Signaling in a Shank2 Rat Model 
of Autism. Front. Mol. Neurosci. 11 (2018).
 17. Lavreysen, H. et al. JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacology 
47, 961–972 (2004).
 18. Würbel, H. Refinement of rodent research through environmental enrichment and systematic randomization. 9 (2007).
 19. Bodden, C. et al. Heterogenising study samples across testing time improves reproducibility of behavioural data. Scientific Reports 9, 
8247 (2019).
 20. Ergaz, Z., Weinstein-Fudim, L. & Ornoy, A. Genetic and non-genetic animal models for autism spectrum disorders (ASD). Reprod. 
Toxicol. Elmsford N 64, 116–140 (2016).
 21. Jiang, Y. & Ehlers, M. D. Modeling Autism by SHANK Gene Mutations in Mice. Neuron 78, 8–27 (2013).
 22. Mei, Y. et al. Adult restoration of Shank3 expression rescues selective autistic-like phenotypes. Nature 530, 481–484 (2016).
 23. Schmeisser, M. J. et al. Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2. Nature 486, 256–260 (2012).
 24. Vicidomini, C. et al. Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice. 
Mol. Psychiatry 22, 689–702 (2017).
 25. Won, H. et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 486, 
261–265 (2012).
 26. Yoo, J., Bakes, J., Bradley, C., Collingridge, G. L. & Kaang, B.-K. Shank mutant mice as an animal model of autism. Philos Trans R Soc 
Lond B Biol Sci 369 (2014).
 27. Fotuhi, M. et al. Differential localization of phosphoinositide-linked metabotropic glutamate receptor (mGluR1) and the inositol 
1,4,5-trisphosphate receptor in rat brain. J. Neurosci. Off. J. Soc. Neurosci. 13, 2001–2012 (1993).
 28. Shigemoto, R., Nakanishi, S. & Mizuno, N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the 
central nervous system: an in situ hybridization study in adult and developing rat. J. Comp. Neurol. 322, 121–135 (1992).
 29. Conn, P. J., Battaglia, G., Marino, M. J. & Nicoletti, F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat. Rev. 
Neurosci. 6, 787–798 (2005).
 30. Aiba, A. et al. Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell 79, 377–388 
(1994).
 31. Hodgson, R. A. et al. Characterization of the selective mGluR1 antagonist, JNJ16259685, in rodent models of movement and 
coordination. Pharmacol. Biochem. Behav. 98, 181–187 (2011).
Acknowledgements
The support of Heidi Huysmans (Janssen Pharmaceutica NV) in the logistics of compound shipping is highly 
appreciated. The present study was supported by the European Autism Interventions - A Multicenter Study for 
Developing New Medications (EU-AIMS) project, which receives support from the Innovative Medicines Initiative 
Joint Undertaking under Grant agreement number 115300, resources of which are composed of financial contributions 
from the European Union’s Seventh Framework Programme (FP7/2007–2013), from the European Federation of 
Pharmaceutical Industries and Associations companies’ in-kind contributions, and from Autism Speaks.
1 0Scientific RepoRtS |         (2019) 9:11602  | https://doi.org/10.1038/s41598-019-47981-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
Author contributions
M.A.-A., R.G., M.M., E.v.D., E.E., W.D., B.K., S.F.d.B., M.C.-D., L.F.J.J.N., M.L., W.v.D., W.S., B.B., D.L.B. and 
M.J.K. were involved in the study design and implementation. M.A.-A., R.G., M.M., E.v.D., E.E., W.D., B.K., 
S.F.d.B., M.C.-D., L.F.J.J.N., M.L., W.v.D., W.S., B.B., D.L.B. and M.J.K. have all reviewed and approved the 
manuscript before submission. M.A-A., R.G., and M.M. conducted the experiments and data analysis. M.C.-D. 
conducted the experiments. B.B., D.L.B. and M.J.K. performed the overall supervision of the project for each 
study site. M.A.-A., S.F.d.B. and M.J.K. wrote the initial version of the manuscript.
Additional information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-47981-0.
Competing Interests: During the study, R.G., M.C-D., and D.L.B. were full time employees and shareholders of 
Pfizer, Inc. D.L.B. is currently a fully time employee and shareholder of Takeda Pharmaceutical Company, Ltd. 
M.M., W.S. and B.B. are fully employed by Roche. E.v.D., W.v.D., and L.P.J.J.N. are fully employed by Noldus 
Information Technology. E.S. is full time employee of Servier. W.D. is fully employed by Janssen Pharmaceutica 
NV and holds stocks and options. B.K. and M.L. are fully employed by Sylics. L.N. is the majority shareholder of 
Noldus Information Technology BV.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
